SGLT2 inhibitors enhanced memory deficits which were primarily attributed to diabetes, reduced epilepsy and severity of seizures, lowered the risk of dementia, and a prominent reduction was observed in neuronal cell death (these effects were observed in laboratory mice models). Here, SLC5A2 is linked to diabetes mellitus.